Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Functional biomaterials for the treatment of periprosthetic joint infection: A systematic review of preclinical animal studies

Zhang Y., Li B., Liu C., Huang T., Rupp M., Brochhausen C.

Systematic Review on Immune Modulation, published in J Orthop Translat (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
J Orthop Translat (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41836549
PMCID
PMC12988533
DOI
10.1016/j.jot.2026.101047

Abstract (original English)

Background Periprosthetic joint infection (PJI) is a serious complication following joint arthroplasty, often leading to implant failure, bone destruction, and high revision rates. Conventional treatments are limited by biofilm persistence and collateral tissue damage. Functional biomaterials, defined as materials with active therapeutic properties such as antimicrobial delivery, biofilm disruption, tissue regeneration, or immunomodulation, offer promising alternatives. This systematic review aims to evaluate the current landscape of functional biomaterials in preclinical PJI models and identify translational challenges. Methods A systematic search of PubMed, Web of Science, and Embase was conducted for studies published between January 2000 and April 2025. Inclusion criteria were preclinical studies using validated animal models of PJI and investigating biomaterials with at least one active therapeutic function. Studies without prosthetic joint components or lacking in vivo data were excluded. Two reviewers independently screened and extracted data, and risk of bias was assessed using SYRCLE's tool. Results 23 studies met the inclusion criteria, covering a range of biomaterial platforms including polymer-based systems, metal-based materials, cement and inorganic materials, nanomaterials, and hydrogels. These materials demonstrated diverse mechanisms and delivery strategies, su

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research